OBJECTIVE: To study antibodies to cyclic citrullinated peptides (anti-CCP) and rheumatoid factor in patients with active, severe extra-articular rheumatoid arthritis (ExRA) compared with controls without ExRA. METHODS: 35 consecutive patients with severe ExRA manifestations according to predefined criteria were studied. 70 patients with rheumatoid arthritis, but no ExRA manifestations, individually matched for age, sex and disease duration, served as controls. Patients were included when ExRA was diagnosed, before any new treatment was started. Anti-CCPs were detected with ELISA, rheumatoid factor was quantified using nephelometry and anti-nuclear antibodies (ANA) were investigated using indirect immune fluorescence. RESULTS: Anti-CCPs were detected in 77% of patients with ExRA versus 56% of controls without ExRA (p = 0.03). Anti-CCP levels also tended to be higher in patients with ExRA (p = 0.09). Rheumatoid factor was detected in 94% v 71% of patients and controls, respectively (p = 0.006), and rheumatoid factor levels were higher in patients with ExRA (median interquartile range (IQR) 245 IU/ml (94-604) v 73 IU/ml (not detected-165); p = 0.001). Levels and occurrence of ANA did not differ between patients with ExRA and controls. Patients with ExRA had higher swollen joint counts and C reactive protein levels, but no correlations were found between anti-CCP or rheumatoid factor levels and these measures within the ExRA group. CONCLUSION: Rheumatoid factor is strongly associated with severe ExRA manifestations in patients with rheumatoid arthritis, and a similar but weaker association exists for anti-CCPs. This suggests a role for rheumatoid factor and anti-CCP in the pathogenesis of ExRA.
OBJECTIVE: To study antibodies to cyclic citrullinated peptides (anti-CCP) and rheumatoid factor in patients with active, severe extra-articular rheumatoid arthritis (ExRA) compared with controls without ExRA. METHODS: 35 consecutive patients with severe ExRA manifestations according to predefined criteria were studied. 70 patients with rheumatoid arthritis, but no ExRA manifestations, individually matched for age, sex and disease duration, served as controls. Patients were included when ExRA was diagnosed, before any new treatment was started. Anti-CCPs were detected with ELISA, rheumatoid factor was quantified using nephelometry and anti-nuclear antibodies (ANA) were investigated using indirect immune fluorescence. RESULTS: Anti-CCPs were detected in 77% of patients with ExRA versus 56% of controls without ExRA (p = 0.03). Anti-CCP levels also tended to be higher in patients with ExRA (p = 0.09). Rheumatoid factor was detected in 94% v 71% of patients and controls, respectively (p = 0.006), and rheumatoid factor levels were higher in patients with ExRA (median interquartile range (IQR) 245 IU/ml (94-604) v 73 IU/ml (not detected-165); p = 0.001). Levels and occurrence of ANA did not differ between patients with ExRA and controls. Patients with ExRA had higher swollen joint counts and C reactive protein levels, but no correlations were found between anti-CCP or rheumatoid factor levels and these measures within the ExRA group. CONCLUSION:Rheumatoid factor is strongly associated with severe ExRA manifestations in patients with rheumatoid arthritis, and a similar but weaker association exists for anti-CCPs. This suggests a role for rheumatoid factor and anti-CCP in the pathogenesis of ExRA.
Authors: C Turesson; P Englund; L T Jacobsson; G Sturfelt; L Truedsson; I Nennesmo; I E Lundberg Journal: Rheumatology (Oxford) Date: 2001-12 Impact factor: 7.580
Authors: Carl Turesson; W Michael O'Fallon; Cynthia S Crowson; Sherine E Gabriel; Eric L Matteson Journal: J Rheumatol Date: 2002-01 Impact factor: 4.666
Authors: E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel Journal: Arthritis Rheum Date: 2000-08
Authors: E Knijff-Dutmer; W Drossaers-Bakker; A Verhoeven; G van der Sluijs Veer; M Boers; S van der Linden; M van de Laar Journal: Ann Rheum Dis Date: 2002-07 Impact factor: 19.103
Authors: R Goldbach-Mansky; J Lee; A McCoy; J Hoxworth; C Yarboro; J S Smolen; G Steiner; A Rosen; C Zhang; H A Ménard; Z J Zhou; T Palosuo; W J Van Venrooij ; R L Wilder; J H Klippel; H R Schumacher; H S El-Gabalawy Journal: Arthritis Res Date: 2000-03-31
Authors: R B Mueller; M Schiff; T Kaegi; A Finckh; S R Haile; H Schulze-Koops; J von Kempis Journal: Clin Rheumatol Date: 2014-07-15 Impact factor: 2.980
Authors: Benjamin J Miriovsky; Kaleb Michaud; Geoffrey M Thiele; James R O'Dell; Grant W Cannon; Gail Kerr; J Steuart Richards; Dannette Johnson; Liron Caplan; Andreas Reimold; Roderick Hooker; Ted R Mikuls Journal: Ann Rheum Dis Date: 2010-05-03 Impact factor: 19.103
Authors: Georgia Barouta; Christina G Katsiari; Ioannis Alexiou; Christos Liaskos; Areti Varna; Dimitrios P Bogdanos; Anastasios E Germenis; Lazaros I Sakkas Journal: Clin Rheumatol Date: 2016-12-10 Impact factor: 2.980